Holly Lofton, MD
Obesity Medicine · New York, NYNPI 1104010511
Payments from drug & device makers
Across 1,331 payments — averaging $2426.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1.5M
- Eli Lilly$1.3M
- Novo Nordisk AS$282K
- Lilly USA, LLC$182K
- Boehringer Ingelheim$28K
- Currax Pharmaceuticals LLC$7K
- plus $12K from 17 others
Across 12 payments — averaging $562.69 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$6K
- Novo Nordisk AS$1K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 492 | $1,450,179 |
| Eli Lilly | 134 | $1,267,282 |
| Novo Nordisk AS | 327 | $281,778 |
| Lilly USA, LLC | 248 | $182,477 |
| Boehringer Ingelheim | 14 | $28,118 |
| Currax Pharmaceuticals LLC | 24 | $7,498 |
| Boehringer Ingelheim France S.a.s. | 32 | $3,565 |
| AbbVie(2 entities) | 2 | $2,275 |
| Intra-sana Laboratories | 7 | $1,999 |
| Madrigal Pharmaceuticals | 5 | $1,885 |
| Amgen | 1 | $652 |
| W. L. Gore & Associates, Inc. | 5 | $361 |
| Johnson & Johnson | 5 | $348 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 15 | $293 |
| Endo Pharmaceuticals Inc. | 4 | $223 |
| Medtronic | 1 | $179 |
| BD | 3 | $103 |
| Eisai Inc. | 3 | $70 |
| Corcept Therapeutics | 3 | $65 |
| Perspectum Diagnostics Ltd | 1 | $53 |
| Shire North American Group Inc | 2 | $41 |
| Nalpropion Pharmaceuticals LLC | 2 | $28 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $23 |
How this compares
Too few obesity medicine providers in New Yorkto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other obesity medicine in New York
- Sarah SchmitzNew York$3K
- Duane FredericksNew York$3K
- Anelise EngelNew York$750
- Ana Aida CaballesNew York$35
- Barbara ConnorSyracuse$1.7M
- Terry VuongSyosset$9K
- Jessica WitteOlean$7K
- Carol SantoroAlbany$1K
- Carl RuoffRoslyn Heights$348
- Thomas DoboszBuffalo$201
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.